

Michael E Thase

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5460105/publications.pdf>

Version: 2024-02-01

251
papers

15,837
citations

36303

51
h-index

18647

119
g-index

262
all docs

262
docs citations

262
times ranked

12468
citing authors

#	ARTICLE	IF	CITATIONS
1	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Australian and New Zealand Journal of Psychiatry, 2023, 57, 93-103.	2.3	3
2	Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry, 2022, 27, 58-72.	7.9	117
3	Does Symptom Linkage Density Predict Outcomes in Cognitive Therapy for Recurrent Depression?. Journal of Psychopathology and Behavioral Assessment, 2022, 44, 469-480.	1.2	2
4	Levels of depressed mood and low interest for two years after response to cognitive therapy for recurrent depression. Behaviour Research and Therapy, 2022, 148, 103996.	3.1	1
5	Clinical research challenges posed by difficult-to-treat depression. Psychological Medicine, 2022, 52, 419-432.	4.5	34
6	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. Psychiatry Research, 2022, 308, 114354.	3.3	4
7	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	4.1	6
8	The Neglected Role of Psychotherapy for Treatment-Resistant Depression. American Journal of Psychiatry, 2022, 179, 90-93.	7.2	20
9	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 145, 615-627.	4.5	9
10	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2022, 328, 151.	7.4	55
11	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. World Journal of Biological Psychiatry, 2021, 22, 483-494.	2.6	32
12	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	4.1	5
13	Quality of life after response to acute-phase cognitive therapy for recurrent depression. Journal of Affective Disorders, 2021, 278, 218-225.	4.1	6
14	CBT MobileWork®: User-Centered Development and Testing of a Mobile Mental Health Application for Depression. Cognitive Therapy and Research, 2021, 45, 287-302.	1.9	25
15	Study design and implementation of the PRrecision Medicine In MEntal health Care (PRIME Care) Trial. Contemporary Clinical Trials, 2021, 101, 106247.	1.8	5
16	Strategies for Optimizing the Treatment of Major Depressive Disorder. , 2021, 70, S11-S19.		1
17	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (American Psychiatric Publishing), 2021, 19, 76-85.	0.8	0
18	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Research, 2021, 296, 113649.	3.3	8

#	ARTICLE	IF	CITATIONS
19	Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. <i>Journal of Affective Disorders</i> , 2021, 282, 1272-1277.	4.1	2
20	Healthcare Provider Perspectives on Bipolar I Disorder Screening and the Rapid Mood Screener (RMS), a Pragmatic, New Tool. <i>CNS Spectrums</i> , 2021, 26, 181-181.	1.2	1
21	The natural history of insomnia: Does sleep extension differentiate between those that do and do not develop chronic insomnia?. <i>Journal of Sleep Research</i> , 2021, 30, e13342.	3.2	7
22	Evaluation of MADRS Severity Thresholds in Patients With Bipolar Depression. <i>CNS Spectrums</i> , 2021, 26, 182-183.	1.2	2
23	Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. <i>CNS Spectrums</i> , 2021, 26, 169-170.	1.2	0
24	Evaluation of MADRS severity thresholds in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2021, 286, 58-63.	4.1	10
25	Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 965-976.	2.1	22
26	The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. <i>Depression and Anxiety</i> , 2021, 38, 1120-1130.	4.1	11
27	Design of the national adaptive trial for PTSD-related insomnia (NAP study), VA cooperative study program (CSP) #2016. <i>Contemporary Clinical Trials</i> , 2021, 109, 106540.	1.8	0
28	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021, 305, 114194.	3.3	1
29	Durability of treatment response to zolpidem using a partial reinforcement regimen: does this strategy require priming?. <i>Sleep Medicine</i> , 2021, 87, 56-61.	1.6	2
30	Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study. <i>Psychopharmacology Bulletin</i> , 2021, 51, 8-30.	0.0	0
31	Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 128.	1.9	8
32	Group ("Project Life Force") versus individual suicide safety planning: A randomized clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100520.	1.1	14
33	The Natural History of Insomnia: the incidence of acute insomnia and subsequent progression to chronic insomnia or recovery in good sleeper subjects. <i>Sleep</i> , 2020, 43, .	1.1	55
34	Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?. <i>Journal of Affective Disorders</i> , 2020, 262, 323-332.	4.1	16
35	Insomnia Symptoms and Suicide-Related Ideation in U.S. Army Service Members. <i>Behavioral Sleep Medicine</i> , 2020, 18, 820-836.	2.1	13
36	OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. <i>International Clinical Psychopharmacology</i> , 2020, 35, 19-28.	1.7	35

#	ARTICLE	IF	CITATIONS
37	M191. EFFECT OF BREXPIRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES. Schizophrenia Bulletin, 2020, 46, S208-S209.	4.3	1
38	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. International Clinical Psychopharmacology, 2020, 35, 313-321.	1.7	9
39	Do patients's cognitive therapy skills predict personality change during treatment of depression?. Behaviour Research and Therapy, 2020, 133, 103695.	3.1	3
40	Charting Sea Changes in Outpatient Pharmacotherapy of Bipolar Disorder. American Journal of Psychiatry, 2020, 177, 651-653.	7.2	1
41	Response to SSRI intervention and amygdala activity during self-referential processing in major depressive disorder. NeuroImage: Clinical, 2020, 28, 102388.	2.7	12
42	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. Journal of Affective Disorders, 2020, 277, 478-485.	4.1	4
43	Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing. BMC Psychiatry, 2020, 20, 518.	2.6	29
44	Improving Cost-effectiveness and Access to Cognitive Behavior Therapy for Depression: Providing Remote-Ready, Computer-Assisted Psychotherapy in Times of Crisis and Beyond. Psychotherapy and Psychosomatics, 2020, 89, 307-313.	8.8	39
45	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. American Journal of Geriatric Psychiatry, 2020, 28, 933-945.	1.2	13
46	181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. CNS Spectrums, 2020, 25, 314-315.	1.2	0
47	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depression and Anxiety, 2020, 37, 485-495.	4.1	9
48	180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectrums, 2020, 25, 313-314.	1.2	0
49	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. Journal of Affective Disorders, 2020, 273, 131-137.	4.1	7
50	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Research, 2020, 290, 113017.	3.3	18
51	Improving Depression Outcome by Patient-Centered Medical Management. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	2
52	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 82, .	2.2	6
53	Patient Response Trajectories in Major Depressive Disorder. Psychopharmacology Bulletin, 2020, 50, 8-28.	0.0	6
54	Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 37-45.	2.2	17

#	ARTICLE	IF	CITATIONS
55	A Propensity Score Analysis of Homework Adherence-Outcome Relations in Cognitive Behavioral Therapy for Depression. <i>Behavior Therapy</i> , 2019, 50, 285-299.	2.4	16
56	Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?. <i>Journal of Affective Disorders</i> , 2019, 242, 150-158.	4.1	10
57	Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure. <i>Value in Health</i> , 2019, 22, 906-915.	0.3	9
58	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. <i>Neuropsychopharmacology</i> , 2019, 44, 2268-2276.	5.4	15
59	Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1907-1916.	1.8	12
60	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	4.1	26
61	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	4.1	13
62	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019, 31, 230-234.	2.1	2
63	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2019, 76, 893.	11.0	472
64	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. <i>American Journal of Psychiatry</i> , 2019, 176, 428-438.	7.2	557
65	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). <i>Journal of Psychiatric Research</i> , 2019, 113, 125-136.	3.1	64
66	49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial. <i>CNS Spectrums</i> , 2019, 24, 202-203.	1.2	1
67	50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results. <i>CNS Spectrums</i> , 2019, 24, 203-204.	1.2	1
68	The Role of Dyadic Discord in Outcomes in Acute Phase Cognitive Therapy for Adults With Recurrent Major Depressive Disorder. <i>Behavior Therapy</i> , 2019, 50, 778-790.	2.4	4
69	Circadian Preference as a Moderator of Depression Outcome Following Cognitive Behavioral Therapy for Insomnia Plus Antidepressant Medications: A Report From the TRIAD Study. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 573-580.	2.6	20
70	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	45
71	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	32
72	Response to the letter entitled "Tachyphylaxis and Desensitization Depression" by Richard Skaff. <i>CNS Spectrums</i> , 2019, 26, 1-2.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 420.	2.6	18
74	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. <i>Journal of Affective Disorders</i> , 2019, 246, 126-131.	4.1	11
75	Could Treatment Matching Patients's Beliefs About Depression Improve Outcomes?. <i>Behavior Therapy</i> , 2019, 50, 765-777.	2.4	2
76	Partner criticism during acute-phase cognitive therapy for recurrent major depressive disorder. <i>Behaviour Research and Therapy</i> , 2019, 113, 48-56.	3.1	3
77	Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. <i>Journal of Affective Disorders</i> , 2019, 246, 775-782.	4.1	26
78	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. <i>Journal of Psychiatric Research</i> , 2019, 111, 59-67.	3.1	197
79	Estimating outcome probabilities from early symptom changes in cognitive therapy for recurrent depression.. <i>Journal of Consulting and Clinical Psychology</i> , 2019, 87, 510-520.	2.0	4
80	Computer-Assisted Cognitive-Behavior Therapy for Depression. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	144
81	Current and Emerging Treatments to Address Unmet Needs in MDD. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	2
82	Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2018, 75, 139.	11.0	451
83	Improving the Efficiency of Psychotherapy for Depression: Computer-Assisted Versus Standard CBT. <i>American Journal of Psychiatry</i> , 2018, 175, 242-250.	7.2	93
84	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	2.6	32
85	HIV Prevalence Among Hospitalized Patients at the Main Psychiatric Referral Hospital in Botswana. <i>AIDS and Behavior</i> , 2018, 22, 1503-1516.	2.7	15
86	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. <i>Journal of Affective Disorders</i> , 2018, 225, 563-568.	4.1	18
87	Relations of Shared and Unique Components of Personality and Psychosocial Functioning to Depressive Symptoms. <i>Journal of Personality Disorders</i> , 2018, 32, 577-602.	1.4	5
88	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2018, 30, 297-305.	2.1	10
89	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 994-1002.	2.3	3
90	Relapse prevention in adults with major depressive disorder treated with vilazodone. <i>International Clinical Psychopharmacology</i> , 2018, 33, 304-311.	1.7	7

#	ARTICLE	IF	CITATIONS
91	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 21, 350-360.	1.9	5
92	Improving Depression Outcome by Patient-Centered Medical Management. <i>American Journal of Psychiatry</i> , 2018, 175, 1187-1198.	7.2	37
93	Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 7-15.	2.2	31
94	Gauging the Use of Second-Generation Antipsychotics: Medicaid Benefits Data Suggest Much Room for Improvement. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 17com11460.	2.2	1
95	Computer-Assisted Cognitive-Behavior Therapy for Depression in Primary Care. <i>primary care companion for CNS disorders, The</i> , 2018, 20, .	0.6	38
96	Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Psychopharmacology Bulletin</i> , 2018, 48, 62-80.	0.0	14
97	Convergence in patient-therapist therapeutic alliance ratings and its relation to outcome in chronic depression treatment. <i>Psychotherapy Research</i> , 2017, 27, 410-424.	1.8	47
98	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 355-365.	2.3	22
99	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. <i>Depression and Anxiety</i> , 2017, 34, 281-290.	4.1	12
100	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017, 22, 203-219.	1.2	97
101	Bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq1 1 0.784314 rgBT /Overl	4.1	10
102	Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 281-288.	1.7	10
103	Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. <i>CNS Spectrums</i> , 2017, 22, 475-483.	1.2	5
104	Clinical correlates of acute bipolar depressive episode with psychosis. <i>Journal of Affective Disorders</i> , 2017, 217, 29-33.	4.1	19
105	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). <i>CNS Drugs</i> , 2017, 31, 421-432.	5.9	61
106	Poor quality of life and functioning in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 10.	2.2	63
107	Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder. <i>Psychiatry Research</i> , 2017, 253, 174-181.	3.3	9
108	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 223, 146-152.	4.1	18

#	ARTICLE	IF	CITATIONS
109	Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 613-618.	2.1	18
110	Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, 773-781.	0.7	24
111	A meta-analysis of the efficacy of venlafaxine extended release 75â€“225â€“mg/day for the treatment of major depressive disorder. <i>Current Medical Research and Opinion</i> , 2017, 33, 317-326.	1.9	11
112	The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2017, 174, 341-348.	7.2	68
113	A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e59-e63.	2.2	64
114	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 433-440.	2.2	29
115	Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 332-340.	1.7	13
116	Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.. <i>Journal of Consulting and Clinical Psychology</i> , 2016, 84, 365-376.	2.0	11
117	A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. <i>European Neuropsychopharmacology</i> , 2016, 26, 979-993.	0.7	123
118	Adjunctive Therapy With Second-Generation Antipsychotics: The New Standard for Treatment-Resistant Depression?. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 180-183.	0.8	5
119	Assessing cognitive therapy skills comprehension, acquisition, and use by means of an independent observer version of the Skills of Cognitive Therapy (SoCT-IO).. <i>Psychological Assessment</i> , 2016, 28, 205-213.	1.5	8
120	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2016, 205, 159-164.	4.1	7
121	Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes. <i>Behaviour Research and Therapy</i> , 2016, 87, 48-57.	3.1	19
122	Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants. <i>Psychiatric Clinics of North America</i> , 2016, 39, 477-486.	1.3	12
123	Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder. <i>Journal of Affective Disorders</i> , 2016, 199, 148-156.	4.1	13
124	Divergent relationship of depression severity to social reward responses among patients with bipolar versus unipolar depression. <i>Psychiatry Research - Neuroimaging</i> , 2016, 254, 18-25.	1.8	49
125	Suicide and sleep: Is it a bad thing to be awake when reason sleeps?. <i>Sleep Medicine Reviews</i> , 2016, 29, 101-107.	8.5	112
126	Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 499-508.	7.2	151

#	ARTICLE	IF	CITATIONS
127	Recommendations for Screening for Depression in Adults. JAMA - Journal of the American Medical Association, 2016, 315, 349.	7.4	15
128	Critical appraisal of selegiline transdermal system for major depressive disorder. Expert Opinion on Drug Delivery, 2016, 13, 659-665.	5.0	10
129	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. Journal of Affective Disorders, 2016, 192, 212-218.	4.1	22
130	Managing Medical Comorbidities in Patients With Depression to Improve Overall Prognosis. Journal of Clinical Psychiatry, 2016, 77, e1496-e1496.	2.2	2
131	Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia. Journal of Clinical Psychiatry, 2016, 77, e1316-e1323.	2.2	106
132	Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.. Psychotherapy, 2015, 52, 268-277.	1.2	18
133	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTSâ€™ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. Depression and Anxiety, 2015, 32, 605-613.	4.1	34
134	Detecting Sudden Gains during Treatment of Major Depressive Disorder: Cautions from a Monte Carlo Analysis. Current Psychiatry Reviews, 2015, 11, 19-31.	0.9	21
135	A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER. Depression and Anxiety, 2015, 32, 451-459.	4.1	38
136	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. Psychoneuroendocrinology, 2015, 62, 18-26.	2.7	70
137	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (stMS) for Treatment of Major Depression. Brain Stimulation, 2015, 8, 787-794.	1.6	145
138	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. Journal of Affective Disorders, 2015, 178, 224-228.	4.1	9
139	Common and Dissociable Dysfunction of the Reward System in Bipolar and Unipolar Depression. Neuropsychopharmacology, 2015, 40, 2258-2268.	5.4	210
140	Can Cognitive Therapy Be Conducted by Computers?. Current Behavioral Neuroscience Reports, 2015, 2, 209-215.	1.3	5
141	Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. Sleep Medicine, 2015, 16, 1160-1168.	1.6	36
142	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2015, 71, 126-133.	3.1	32
143	Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2015, 76, e1147-e1147.	2.2	6
144	US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine. Journal of Clinical Psychiatry, 2015, 76, e120-e121.	2.2	3

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1224-1231.	2.2	137
146	Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1232-1240.	2.2	135
147	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 144-148.	4.1	15
148	You Gotta Work at It. <i>Clinical Psychological Science</i> , 2014, 2, 455-471.	4.0	133
149	Neural substrates of trait ruminations in depression.. <i>Journal of Abnormal Psychology</i> , 2014, 123, 35-48.	1.9	121
150	The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments. <i>World Psychiatry</i> , 2014, 13, 244-250.	10.4	43
151	Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 351-356.	1.7	37
152	Large-Scale Study Suggests Specific Indicators for Combined Cognitive Therapy and Pharmacotherapy in Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2014, 71, 1101.	11.0	3
153	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , 2014, 11, 494-502.	1.6	9
154	Computer-assisted cognitive behavior therapy for depression.. <i>Psychotherapy</i> , 2014, 51, 191-197.	1.2	51
155	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	4.1	18
156	Extreme Nonresponse to Acute Phase Cognitive Therapy for Depression: An Attempt to Replicate and Extend. <i>Behavior Therapy</i> , 2014, 45, 300-313.	2.4	8
157	Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 167, 37-43.	4.1	14
158	Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.. <i>Journal of Consulting and Clinical Psychology</i> , 2014, 82, 1049-1059.	2.0	18
159	Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 539-544.	3.7	48
160	Translating Clinical Science Into Effective Therapies. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e11.	2.2	3
161	A Review of Vilazodone, Serotonin, and Major Depressive Disorder. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.6	11
162	Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 151, 722-727.	4.1	76

#	ARTICLE	IF	CITATIONS
163	The cardiovascular safety profile of escitalopram. <i>European Neuropsychopharmacology</i> , 2013, 23, 1391-1400.	0.7	43
164	Antidepressant Combinations: Cutting Edge Psychopharmacology or Passing Fad?. <i>Current Psychiatry Reports</i> , 2013, 15, 403.	4.5	11
165	Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 10.	2.2	28
166	Quetiapine XR monotherapy in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2013, 28, 113-120.	1.7	7
167	Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 121-131.	2.4	27
168	Social Skills Training for Depression and Comparative Efficacy Research: A 30-Year Retrospective. <i>Behavior Modification</i> , 2012, 36, 545-557.	1.6	9
169	Barriers to Cognitive Behavioral Therapy Homework Completion Scale—Depression Version: Development and Psychometric Evaluation. <i>International Journal of Cognitive Therapy</i> , 2012, 5, 219-235.	2.2	10
170	EXTENDED RELEASE QUETIAPINE FUMARATE IN MAJOR DEPRESSIVE DISORDER: ANALYSIS IN PATIENTS WITH ANXIOUS DEPRESSION. <i>Depression and Anxiety</i> , 2012, 29, 574-586.	4.1	32
171	Risk for Partner Victimization and Marital Dissatisfaction Among Chronically Depressed Patients. <i>Journal of Family Violence</i> , 2012, 27, 75-85.	3.3	7
172	Strategies for Increasing Treatment Adherence in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e08.	2.2	9
173	Bipolar Disorder Maintenance Treatment. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e15.	2.2	5
174	Using Adjunctive Treatments When First-Line Antidepressants Fail. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e01.	2.2	4
175	MAOIs and Depression Treatment Guidelines. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e24.	2.2	10
176	Applying Antidepressant Study Results to Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e21.	2.2	1
177	If at First You Don't Succeed. <i>Drugs</i> , 2011, 71, 43-64.	10.9	382
178	Assessing the "true" effect of active antidepressant therapy <i>vs.</i> placebo in major depressive disorder: use of a mixture model. <i>British Journal of Psychiatry</i> , 2011, 199, 501-507.	2.8	65
179	Cognitive-behavioral therapy reduced risk for recurrence in patients recently hospitalized with cardiovascular disease events. <i>Annals of Internal Medicine</i> , 2011, 154, JC5.	3.9	0
180	Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study. <i>Journal of Psychiatric Research</i> , 2011, 45, 412-420.	3.1	22

#	ARTICLE	IF	CITATIONS
181	The Small Specific Effects of Antidepressants in Clinical Trials: What Do They Mean to Psychiatrists?. <i>Current Psychiatry Reports</i> , 2011, 13, 476-482.	4.5	15
182	Skills of Cognitive Therapy (SoCT): A new measure of patients' comprehension and use.. <i>Psychological Assessment</i> , 2011, 23, 578-586.	1.5	70
183	Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e18.	2.2	47
184	Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients. primary care companion for CNS disorders, <i>The</i> , 2011, 13, .	0.6	8
185	The Role of Neurobiologic Processes in Symptoms of Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e08.	2.2	0
186	Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. <i>International Clinical Psychopharmacology</i> , 2010, 25, 189-198.	1.7	70
187	Dysfunctional Attitudes, Attributional Styles, and Phase of Illness in Bipolar Disorder. <i>Cognitive Therapy and Research</i> , 2010, 34, 24-34.	1.9	18
188	No evidence for switching antidepressants in treatment-resistant depressed patients. <i>Evidence-Based Medicine</i> , 2010, 15, 120-121.	0.6	0
189	Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 451-462.	2.2	36
190	The Role of Neurobiologic Processes in Treating Depression. <i>Journal of Clinical Psychiatry</i> , 2010, 71, e28.	2.2	0
191	Does concomitant antidepressant therapy enhance response to electroconvulsive therapy?. <i>Current Psychiatry Reports</i> , 2009, 11, 423-425.	4.5	0
192	An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder. <i>CNS Spectrums</i> , 2009, 14, 144-154.	1.2	60
193	Diagnosis and Treatment of a Major Depressive Episode. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e37.	2.2	3
194	Pharmacotherapeutic Treatment Strategies for Antidepressant Nonresponse. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e42.	2.2	2
195	Treating Major Depression: Antidepressant Algorithms. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e46.	2.2	6
196	Newer Medications for Complicated Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e33.	2.2	7
197	Evaluating Atypical Antipsychotics in the Treatment of Refractory Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e14.	2.2	2
198	Update on Partial Response in Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 4-9.	2.2	22

#	ARTICLE	IF	CITATIONS
199	Pharmacologic and therapeutic strategies in treatment-resistant depression. Augmentation strategies. CNS Spectrums, 2009, 14, 7-10.	1.2	2
200	Do antidepressants really work? A clinicians'™ guide to evaluating the evidence. Current Psychiatry Reports, 2008, 10, 487-494.	4.5	17
201	A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension. Journal of Clinical Psychopharmacology, 2008, 28, 302-307.	1.4	33
202	Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression. Journal of Clinical Psychopharmacology, 2008, 28, 13-20.	1.4	203
203	Management of Patients With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2008, 69, e08.	2.2	74
204	Maintenance Therapy for Bipolar Disorder. Journal of Clinical Psychiatry, 2008, 69, e32.	2.2	10
205	Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 440-447.	0.6	39
206	Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacology Bulletin, 2008, 41, 58-85.	0.0	45
207	Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Journal of Clinical Psychiatry, 2008, 69, 1928-36.	2.2	21
208	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 739-752.	7.2	297
209	Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychopharmacology, 2007, 27, 672-676.	1.4	100
210	BOLDER II study of quetiapine therapy for bipolar depression. Future Neurology, 2007, 2, 373-377.	0.5	0
211	Augmentation Strategies for Depression: History and Concepts. CNS Spectrums, 2007, 12, 3-5.	1.2	10
212	Treatment of refractory bipolar depression. Current Psychiatry Reports, 2007, 9, 495-496.	4.5	1
213	STEP-BD and bipolar depression: What have we learned?. Current Psychiatry Reports, 2007, 9, 497-503.	4.5	50
214	On the propriety of collaborations between academicians and the pharmaceutical industry: an alternate viewpoint. World Psychiatry, 2007, 6, 29-31.	10.4	8
215	Recognition and diagnosis of atypical depression. Journal of Clinical Psychiatry, 2007, 68 Suppl 8, 11-6.	2.2	19
216	Treatment of anxiety disorders with venlafaxine XR. Expert Review of Neurotherapeutics, 2006, 6, 269-282.	2.8	27

#	ARTICLE	IF	CITATIONS
217	The role of homework in cognitive behavior therapy of depression.. Journal of Psychotherapy Integration, 2006, 16, 162-177.	1.1	43
218	Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options. CNS Spectrums, 2006, 11, 12-21.	1.2	77
219	Treatment with Venlafaxine Extended Release After SSRI Nonresponse or Intolerance. Journal of Clinical Psychopharmacology, 2006, 26, 250-258.	1.4	52
220	Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: <i>A 12-Week, Open-label, Extension Study</i>. CNS Spectrums, 2006, 11, 93-102.	1.2	55
221	Bipolar depression: Diagnostic and treatment considerations. Development and Psychopathology, 2006, 18, 1213-30.	2.3	39
222	A Double-blind Comparison Between Bupropion XL and Venlafaxine XR. Journal of Clinical Psychopharmacology, 2006, 26, 482-488.	1.4	80
223	Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression. Journal of Clinical Psychopharmacology, 2006, 26, 600-609.	1.4	455
224	Pharmacotherapy of bipolar depression: An update. Current Psychiatry Reports, 2006, 8, 478-488.	4.5	34
225	Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology, 2006, 31, 1841-1853.	5.4	572
226	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1905-1917.	7.2	4,241
227	Depression and sleep: pathophysiology and treatment. Dialogues in Clinical Neuroscience, 2006, 8, 217-226.	3.7	129
228	The Failure of Evidence-Based Medicine to Guide Treatment of Antidepressant Nonresponders. Journal of Clinical Psychiatry, 2006, 67, 1833-1835.	2.2	4
229	Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine. Journal of Clinical Psychopharmacology, 2005, 25, 132-140.	1.4	101
230	Correlates and consequences of chronic insomnia. General Hospital Psychiatry, 2005, 27, 100-112.	2.4	82
231	Bipolar Depression: Issues in Diagnosis and Treatment. Harvard Review of Psychiatry, 2005, 13, 257-271.	2.1	74
232	Relative Antidepressant Efficacy of Venlafaxine and SSRIs: Sex-Age Interactions. Journal of Women's Health, 2005, 14, 609-616.	3.3	168
233	Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry, 2005, 66, 974-981.	2.2	262
234	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Contemporary Clinical Trials, 2004, 25, 119-142.	1.9	898

#	ARTICLE	IF	CITATIONS
235	Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence. <i>CNS Spectrums</i> , 2004, 9, 808-821.	1.2	61
236	Introduction: the dual-action debate: does pharmacology matter?. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 17, 3-4.	2.2	0
237	Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. <i>Psychiatric Clinics of North America</i> , 2003, 26, 495-518.	1.3	16
238	Treatment of Recurrent Depression. <i>CNS Drugs</i> , 2003, 17, 1119-1122.	5.9	3
239	Is academic psychiatry for sale?. <i>British Journal of Psychiatry</i> , 2003, 182, 388-390.	2.8	25
240	Evaluating antidepressant therapies: remission as the optimal outcome. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 13, 18-25.	2.2	24
241	Achieving remission and managing relapse in depression. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 18, 3-7.	2.2	18
242	The next step forward: a move toward evidence, and away from fear of the industry. <i>Psychopharmacology Bulletin</i> , 2002, 36, 4-5.	0.0	34
243	Remission as the critical outcome of depression treatment. <i>Psychopharmacology Bulletin</i> , 2002, 36, 12-25.	0.0	16
244	NATURAL HISTORY AND PREVENTATIVE TREATMENT OF RECURRENT MOOD DISORDERS. <i>Annual Review of Medicine</i> , 1999, 50, 453-468.	12.2	83
245	Title is missing!. <i>Cognitive Therapy and Research</i> , 1999, 23, 381-399.	1.9	151
246	Patterns of Suicidality and Alcohol Use in Alcoholics with Major Depression. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1451-1455.	2.4	76
247	Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. <i>Depression</i> , 1994, 2, 152-168.	0.6	17
248	TREATMENT OF SEVERE DEPRESSION WITH COGNITIVE BEHAVIOR THERAPY. , 1994, , .		0
249	Management commentary. , 0, , 278-281.		0
250	Therapeutic Armamentarium. , 0, , 861-875.		0
251	Cognitive and Behavioral Therapies. , 0, , 1920-1947.		3